William Blair Initiates Coverage On Athersys to Outperform

William Blair Initiates Coverage On Athersys(ATHX). The shares have been rated Outperform. The rating by the stock financial advisor at William Blair was issued on Mar 28, 2017 in a research report to their Investors and Clients.

In a different note, Needham said it Initiates Coverage On Athersys, according to a research note issued on Feb 7, 2017. In the research note, the firm Announces the price-target to $7 per share. The shares have been rated ‘Buy’ by the firm.

Athersys (ATHX) made into the market gainers list on Fridays trading session with the shares advancing 0.88% or 0.01 points. Due to strong positive momentum, the stock ended at $1.14, which is also near the day’s high of $1.15. The stock began the session at $1.13 and the volume stood at 5,25,588 shares. The 52-week high of the shares is $2.69 and the 52 week low is $1.02. The company has a current market capitalization of $125 M and it has 10,98,03,921 shares in outstanding.

Athersys(ATHX) last announced its earnings results on Mar 9, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $983.000K. Analysts had an estimated revenue of $420.000K. Earnings per share were $-0.1. Analysts had estimated an EPS of $-0.08.

Several Insider Transactions has been reported to the SEC. On Feb 1, 2017, Ismail Kola (director) purchased 15,000 shares at $1.01 per share price.Also, On Feb 1, 2017, Jordan Davis (director) purchased 247,500 shares at $1.01 per share price.On Feb 1, 2017, Laura K Campbell (Senior Vice Pres Finance) purchased 20,000 shares at $1.01 per share price, according to the Form-4 filing with the securities and exchange commission.

Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders neurological conditions cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications such as obesity related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas including the treatment of ARDS. Its current programs include Ischemic Stroke Acute Myocardial Infarction Acute Respiratory Distress Syndrome Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs it is also conducting or supporting clinical activity in other areas such as solid organ transplant.

Add Comment